Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK negative
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ALK positive (74)
EGFR negative + ALK negative (4)
EGFR expression + ALK positive (3)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
ALK positive (74)
EGFR negative + ALK negative (4)
EGFR expression + ALK positive (3)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
ALK negative
Non Small Cell Lung Cancer
ALK negative
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
ALK negative
Non Small Cell Lung Cancer
ALK negative
Non Small Cell Lung Cancer
pembrolizumab + atezolizumab
Sensitive: B - Late Trials
pembrolizumab + atezolizumab
Sensitive
:
B
pembrolizumab + atezolizumab
Sensitive: B - Late Trials
pembrolizumab + atezolizumab
Sensitive
:
B
ALK negative
Non-Hodgkin’s Lymphoma
ALK negative
Non-Hodgkin’s Lymphoma
etoposide IV
Sensitive: C3 – Early Trials
etoposide IV
Sensitive
:
C3
etoposide IV
Sensitive: C3 – Early Trials
etoposide IV
Sensitive
:
C3
ALK negative
Non Small Cell Lung Cancer
ALK negative
Non Small Cell Lung Cancer
sintilimab
Sensitive: C3 – Early Trials
sintilimab
Sensitive
:
C3
sintilimab
Sensitive: C3 – Early Trials
sintilimab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login